Should older people get boosters? The data from Israel indicate that this needs to be given strong consideration in those above 60 years old who were fully vaccinated by the end of January.
Sharon Alroy-Preis, MD, MPH, MBA, the director of Public Health Services in Israel stated on Face the Nation yesterday that they are seeing evidence of the effectiveness of the Pfizer/BioNTech COVID-19 vaccine waning over time. Overall, it is still very effective in preventing hospitalizations and deaths, with the exception of those over 60 who have been fully vaccinated before the end of January 2021. Below is a slide from the Ministry of Health Israel.
Most of the infections in Israel are caused by the Delta variant. Overall if there was a breakthrough infection: 8.6% hospitalized and 2% died. However, the test positivity rate appears to be low, about 0.3%, indicating that vaccines afford protection against infection.
As can be seen in the right-hand side of the grey/back graphs in the slide below, severe cases and deaths are reappearing in vaccinated individuals above the age of 60, but still staying at a low level in those individuals under the age of 60.
The initial deaths and hospitalizations shown in the data in the above slide may be due to immunocompromised individuals who did not respond well to the vaccine. But in the elderly, this pattern is now recurring.
As previously reported by Infection Control Today®, the vaccine efficacy rate in preventing infections was 39% and symptomatic infections, 41%. Efficacy in preventing hospitalizations along with severe COVID-19 (including deaths) is approximately 88% and 91%, respectively.
Needless-to-say we need to have robust data being produced by the Centers for Disease Control and Prevention (CDC). In an interview on CNN last weekend, Leana Wen, MD, an emergency physician and visiting professor of health policy at George Washington University, stated that “we are blind without data. This happened during the Trump administration, and we called out the Trump administration for it. Just because you are not testing does not mean the cases do not exist. It just means you do not know about it.”
The CDC data which Wen and epidemiologists have called for includes:
Some data are starting to emerge. On Face the Nation, Alroy-Preis stated the ability to transmit the disease in vaccinated individuals was 50% lower than non-vaccinated individuals. And a small report from Israel studying health care workers with breakthrough infections found 19% still had residual symptoms at greater than 6 weeks after their diagnosis, including symptoms of “prolonged loss of smell, persistent cough, fatigue, weakness, dyspnea, or myalgia.”
The take-home message from the Israel data is that the Pfizer/BioNTech vaccine is highly effective in preventing severe disease in those who have been vaccinated, with the possible exception of those over 60 years of age who were fully vaccinated before the end of January.
Those who are not vaccinated need to become vaccinated and, similar to Israel, those over the age of 60 who were fully vaccinated before January of this year, should be considered for a booster.
Four Years After COVID-19: What Has the Infection Prevention Community Learned?
March 15th 2024Four years ago today, March 15, 2020, the COVID-19 lockdown began, and since then, the world has undergone significant changes. It has been a terrifying experience for everyone, especially for the infection prevention community, both within and outside of the health care sector. However, a crucial question remains unanswered: What has the infection prevention community learned from this pandemic, and where does it go from here?
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
“A Marathon and a Sprint”: Passing Surgical Smoke Legislation
March 9th 2024At the AORN’s International Surgical Conference & Expo 2024, a presentation on surgical smoke drew applause and strong emotion about the continuing fight for legislation on removing surgical smoke from operating rooms. Infection Control Today was there to tell you what happened.
Health at Risk: The Impact of Antimicrobial Resistance From a Global to Local Health Perspective
March 6th 2024Discover the critical role infection preventionists play in combating multidrug-resistant organisms, from the impact on patient care to the challenges of treatment, and the evolving landscape of antimicrobial resistance with Katharine J Hoffman, MPH, CIC.